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Background: In 2016, WHO passed the Global Health Sector Strategy on Viral Hepatitis (GHSS), calling for its
elimination by 2030. Two years later, Turkey approved a strategy to reach the WHO targets. This study reports new
national prevalence data, breaks it down by subpopulation, and models scenarios to reach HCV elimination.
Methods: Literature was reviewed for estimates of HCV disease burden in Turkey. They were discussed with
stakeholders and used as inputs to develop a disease burden model. The infected population was estimated by
sequelae for the years 2015–2030. Three scenarios were developed to evaluate the disease burden in Turkey: a Base
2017 scenario, representing the current standard of care in Turkey; an increased treatment scenario, representing
the impact of improved access to DAAs; and a WHO targets scenario, which meet the WHO GHSS viral hepatitis
targets of a 65% reduction in mortality and 90% diagnosis rate of the infected population by 2030.
Results: At the beginning of 2017, 271,000 viremic infections were estimated. Of these, 58,400 were diagnosed and
10,200 treated. Modelling results showed that, with the current treatment paradigm in Turkey, by 2030 the total
number of viremic HCV infections would decline by 35%, while liver-related deaths, hepatocellular carcinoma (HCC),
and decompensated cirrhosis would decrease by 10–25%. In the increased treatment scenario, by 2030 viremic
HCV infections would decrease by 50%; liver-related deaths, HCC and decompensated cirrhosis would
decrease by 45–70%. In the WHO targets scenario, HCV infections would decrease by 80%; sequelae would
decrease by 80–85%. Data on disease burden in micro-elimination target subpopulations are largely
unavailable.
Conclusions: To meet the WHO Global Health Sector Strategy targets for the elimination of HCV, Turkey
needs to increase treatment. Better data are needed as well as countrywide access to DAAs.
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The introduction of all-oral second-generation direct-
acting antiviral (DAA) drugs in 2013 dramatically chan-
ged treatment paradigms and outcomes of hepatitis C
virus (HCV) infection worldwide. Very high sustained© The Author(s). 2020 Open Access This artic
which permits use, sharing, adaptation, distrib
appropriate credit to the original author(s) and
changes were made. The images or other thir
licence, unless indicated otherwise in a credit
licence and your intended use is not permitte
permission directly from the copyright holder
The Creative Commons Public Domain Dedica
data made available in this article, unless othe
* Correspondence: Jeffrey.Lazarus@isglobal.org
9Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of
Barcelona, Calle del Rossellón 132, 4th Floor, ES-08036 Barcelona, Spain
10Centro de Investigación Biomédica en Red en Epidemiología y Salud
Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
Full list of author information is available at the end of the articlevirologic response (SVR) rates (≥95%) can be achieved
with 8–12 weeks of DAA treatment [1]. These high
treatment success rates led the World Health
Organization (WHO) to call for the elimination of viral
hepatitis in their 2016 Global health sector strategy on viral
hepatitis (GHSS) and set targets for the elimination of
HCV infection by 2030 – a 90% reduction in new HCV in-
fections and a 65% reduction in mortality due to HCV [2].
Eliminating HCV countrywide requires the inclusion
of diverse stakeholders – governmental authorities at the
national, subnational, and local levels, associations ofle is licensed under a Creative Commons Attribution 4.0 International License,
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Table 1 Estimations used to model the burden of HCV in
Turkey
a. Base 2017 scenario
2015 2016 2017 &
2018
2018 2019 ≥2020
Treated 4200 5600 10,200 9500 8800 5600
Newly
diagnosed
5500 5500 5500 5500 5500 5500








SVR 49% 97% 99% 99% 99% 99%
b. Increased treatment scenario










5500 5500 5500 5500 5500 5500








SVR 49% 97% 99% 99% 99% 99%
c. WHO targets scenario










5500 5500 5500 6000 18,000 18,000








SVR 49% 97% 99% 99% 99% 99%
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risk populations. It calls for complex planning in terms
of public affairs, and the need for human and financial
resources that may not be readily available [3]. Before
attempting nationwide elimination, breaking down na-
tional elimination goals into smaller, achievable goals for
individual population segments may be more realistic
[3]. Such micro-elimination strategies for selected popu-
lations are easier to develop and implement; targets can
be achieved in a shorter period of time; and fewer finan-
cial resources are required at the outset. Further, they
encourage health-care providers and other stakeholders
to develop a broader programme to achieve the WHO
elimination targets following the success of micro-
elimination plans.
The prevalence of HCV infection in Turkey ranged
from 275,000 (0.5%) to 494,000 (0.96%) in nationwide
epidemiologic studies in 2009–10 [4, 5]. Only 15,000–
20,000 patients have been treated with DAAs from mid-
2016 to mid-2018.
Two second-generation DAA regimens were approved
by the Turkish Ministry of Health in 2015 and treatment
with these has been reimbursed since 2016. An HCV-
infected patient who has been previously treated with
other antiviral treatment is also eligible for reimburse-
ment of DAA treatment without any limitation.
However, to start DAA treatment, a treatment-naive
HCV-infected patient is required to be at least in fibrosis
stage F1 (Ishak scoring system) documented by a liver
biopsy, a procedure not favored by most patients. In
addition, the national reimbursement authority reim-
burses DAAs prescribed only by infectious disease or
gastroenterology specialists from tertiary referral hospi-
tals, which are only in 41 cities of Turkey, greatly limit-
ing access. Treatment is delivered to patients only via
pharmacies in these hospitals.
The Turkish Ministry of Health published a highly
comprehensive national HCV elimination plan in Octo-
ber 2018, but how it will be implemented is unknown
[6]. To examine the feasibility of achieving the WHO
targets, including through a national micro-elimination
programme, reliable disease burden estimates are needed
[7] in the general population and in target subpopula-
tions. This study reports new national prevalence data
and breaks it down by subpopulation, employing a
micro-elimination approach, and models the feasibility
of eliminating viremic HCV by 2030.
Methods
In December 2017–January 2018, a literature search was
conducted to identify estimates of hepatitis C preva-
lence, viremia, genotype distribution, leave in diagnosis,
and treatment rates in Turkey. A Delphi process was
then initiated in January 2018 with a team of countryexperts to assess the body of evidence and reach consen-
sus on all inputs of the model and sub-population level
estimates. The group consisted of 44 physicians repre-
senting infectious disease and gastroenterological profes-
sional associations (see the Acknowledgements section),
and four meetings were held in Ankara, Istanbul and
Izmir during the study process.
Disease burden model
An Excel-based Markov HCV disease burden model was
developed [8]. Population, mortality, and historical data
specific to Turkey were used to calibrate the model, and
the infected population was estimated by HCV sequelae
for the years 2015–2030 (Table 1). The model reflects
the natural history of HCV infection, in that it begins
with the annual number of acute infections that progress
to chronic HCV, after considering spontaneous clear-
ance. The progression of these new cases is followed
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by age and sex), accounting for treatment, cure, and
background mortality. When available, reported or cal-
culated annual estimates of new infections are used.
However, these data were not available in Turkey and,
thus, new cases by age and sex were back-calculated
using known prevalence in a given year. Considering
that the model calculated all-cause mortality, liver-
related mortality, and cured cases, Solver, an optimization
add-in by Excel, was used to determine the average num-
ber of new infections per year dating back to 1950. Then,
an annual relative incidence value was used to describe
the change in the number of new infections from 1950
until the year of known HCV prevalence.
Discussions with experts were used to inform the
trend in new infections, considering risk factors such
as blood transfusion and injection drug use. After
these calculations were complete, the age and sex dis-
tribution of acute infections were calculated to match
the age and sex distribution of the known prevalent
population and linearly trended in five-year incre-
ments. The total number of cases by HCV sequelae
was calculated by multiplying the total number of
cases at a particular stage by a progression rate,
adjusting for ageing, all-cause mortality, and cured in
a given year. All cause mortality rates by age and sex
were gathered from the United Nations mortality
database and adjusted for incremental increase in
mortality due to injection drug use and transfusion.
The number of active people who inject drugs
(PWID) and HCV prevalence among PWID was gath-
ered through published studies and divided by the
total HCV infected population in order to estimate
the proportion of all viremic HCV infections among
active PWID.
Inputs for estimating the disease burden
There were an estimated 396,400 cases with anti-
HCV positivity (0.52% prevalence) in 2013 [9]. Apply-
ing a viremic prevalence rate of 71.7% [9], 284,200 in-
dividuals were estimated to be chronically infected
with HCV in 2013 in the general Turkish population,
resulting in a viremic prevalence of 0.37%. The model
assumes that 86.7% of infections are genotype 1 (8.8%
G1a, 70.2% G1b, and 7.7% G1 other) and 6.4% are
genotype 3, based on a study of approximately 1,000
patients [10]. The age and sex distribution of the in-
fected population was taken from a study conducted
in 2009–2010 in 23 urban and rural areas of Turkey
[4]. About 59,700 viremic infections were diagnosed
as of 2017, and of those, 5,500 viremic patients are
newly diagnosed each year (expert input). Industry
data report that 5,600 patients were treated in 2016;
all had ≥F3 fibrosis. In 2017, treatment eligibility wasexpanded to patients ≥F1, allowing for 10,200 patients
to be treated in that year. Literature sources informed
rates of infection associated with injecting drug use
and blood transfusion [11], two HCV risk factors as-
sociated with a higher mortality. These values were
agreed upon as the best acceptable figures.
Once the current HCV disease burden was estimated,
strategies to minimize the future burden were analyzed.
Two intervention scenarios that expand access and in-
crease rates of care above current levels were compared
to a historical base case through the year 2030.Scenarios
The “Base 2017” scenario represents the current treat-
ment paradigm in Turkey (Table 1a). Without additional
efforts to identify new cases and expand treatment eligi-
bility, it was assumed that a diminishing pool of
treatment-eligible patients would result in a 50% decline
in the annual number of patients treated by 2020. After
2020, the annual number of treated patients is assumed
to remain constant. Patients aged 17–91 years were eli-
gible for treatment, and the SVR rate was estimated to
be 99% in 2018 [12].
An “Increased Treatment” scenario was created to
assess the impact of improved access to DAAs in the
coming years (Table 1b). Treatment was expanded to
11,000 patients annually beginning in 2019, regardless
of fibrosis stage. However, as no national screening
strategies have been developed for Turkey, the annual
number of newly diagnosed patients was assumed to
remain constant. Because of this, the model would
run out of eligible patients by 2027. Eligible treatment
age and SVR rates remained the same as the Base
2017 scenario.
A third scenario was developed in order to meet the
WHO GHSS viral hepatitis targets of a 65% reduction in
mortality and 90% diagnosis rate of the infected popula-
tion by 2030 [2]. To do this, the number of treated pa-
tients was increased to 16,000 annually starting in 2021
(Table 1c). The number of diagnosed patients was also
increased to 18,000 annually by the same year. Incidence
was reduced starting in 2021 to achieve an overall 90%
reduction in annual new infections by 2030.Estimating the burden of prevalent HCV infection in
priority subpopulations targeted for micro-elimination
Ways to incorporate micro-elimination targets within
this wider framework of national elimination strategies
were proposed through the series of expert meetings. In
Turkey, the potential priority at-risk populations that
can be targeted for HCV micro-elimination could be cat-
egorized into three broad groups: (i) patients at high risk
who are already in the health-care system; (ii) people at
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people with high-risk behaviours (Table 2).
Results
HCV disease burden in special populations
Through discussions with over 40 experts at four meet-
ings across the country, coupled with a literature review,
the following sub-population level estimates were
projected.
Patients at high risk who are already in the health-care
system
Patients with advanced liver disease Advanced liver
disease is defined by significant fibrosis (>F3 assessed by
either APRI score > 1.5, FIB-4 > 3.2, transient elastogra-
phy > 9.5 kPa or biopsy > METAVIR stage F3). Estimates
of the disease burden showed a compensated cirrhosis
prevalence of 13%, and a decompensated cirrhosis preva-
lence of 1.6% among viremic patients [13].
Patients with advanced chronic kidney disease No
published data are available on the number of patients
with HCV who undergo dialysis [14–17]. However, the
Turkish Society of Nephrology reported that almost 60,
000 patients undergo some kind of dialysis routinely in
the 860 dialysis centres in Turkey and, based on the data
from 72 centres, 5.5% of those undergoing hemodialysis
are positive for anti-HCV [18].
Patients with certain inherited blood disorders (i.e.
hemophilia, thalassemia) In 2014, there were 6,150 pa-
tients with hemophilia, Von Willebrand disease or other
bleeding disorders, and at least 4,500 patients with beta-
thalassemia in 2007 [19, 20]. How many of these are
HCV-infected is not known. In 2005, 14 of 70 patientsTable 2 Potential prioritized at-risk populations that can be
selected for micro-elimination in Turkey
1. Patients with high risk and already in the health-care system
a. Patients with advanced liver disease
b. Patients with advanced chronic kidney disease
c. Patients with certain hematologic diseases (i.e. haemophilia,
thalassemia)
d. Transplant recipients
e. Persons diagnosed with HCV but not treated yet
2. People at high risk due to demographic characteristics
a. People who were born before 1960
b. People from certain geographic areas
3. People with high-risk behaviours
a. People who inject drugs
b. Prisoners(20%) with thalassemia major were anti-HCV positive,
five (7.1%) were HCV RNA positive [21]. A publication
in 2018 stated that among 53 patients with thalassemia
major, two were anti-HCV positive – Syrians, who had
immigrated from Syria [22]. A study in 2017 among
1,270 patients in 33 centres found that 21.7% had a
history of blood transfusion [23].
Transplant recipients and patients on immune-
suppressive treatment No data are available on the
number infected with HCV among this population. Min-
istry of Health data show that HCV prevalence was 9–
11% among transplant recipients between 2011 and
2015.
Persons who have already been diagnosed with HCV
but not treated yet There are no published data on the
number of patients who have been diagnosed with HCV
but not treated yet.
People at high risk due to demographic characteristics
People who were born before 1960 [24] There are about
19.5 million people in this group, but it is not known how
many are currently infected with HCV. People who received
blood or blood products or underwent an organ transplant-
ation before 1996 may also be included as a risk group.
People from certain geographic areas Living in spe-
cific regions of south-eastern Turkey is associated with a
2.1-fold increase in the chances of being anti-HCV posi-
tive compared to living in other areas of Turkey [4]. An-
other study showed 11% anti-HCV positivity in Nevsehir
in the region of Cappadocia [25].
People with high-risk behaviors
People who inject drugs The prevalence of anti-HCV
positivity was estimated to be around 40% in 2015 [26].
Prisoners Anti-HCV positivity was 17.7% among pris-
oners [27].
Estimates of disease burden
Additionally, using the aforementioned disease burden
model, the following general population level estimates
were projected and the impact of three different man-
agement scenarios assessed.
The number of viremic infections estimated at the be-
ginning of 2017 was 271,000. Of these, 58,400 were diag-
nosed and 10,200 treated. At a 99% SVR rate, 10,100 of
the 10,200 treated were estimated to be cured (Fig. 1).
Fig. 1 The hepatitis C cascade of care, including the total number of viremic infections, the number of diagnosed patients, and the number of
patients treated and cured, in Turkey in 2017
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of HCV infections started rising from the age of 15 years,
peaked at 35–44 years and gradually declined thereafter.
Disease burden scenarios
Base scenario By 2030, the total number of viremic
HCV infections would decline by 35%. The number of
HCV infected people with hepatocellular carcinomaFig. 2 Total infected cases, liver-related deaths, prevalent HCC and prevale(HCC) and decompensated cirrhosis cases would de-
crease by 10–25% by the same year. (Fig. 2 and Table 3).Increased treatment scenario By 2030, the total num-
ber of viremic HCV cases would decrease by 50%; and
liver-related deaths, prevalent HCC and prevalent de-
compensated cirrhosis would decrease by 45–70% (Fig. 2
and Table 3).nt decompensated cirrhosis in Turkey, 2015–2030
Table 3 Total infected cases, decompensated cirrhosis, HCC and




Increased treatment 278,000 142,000
WHO targets 278,000 52,000
Prevalent Decompensated cirrhosis
Base 1500 1300
Increased treatment 1500 700
WHO targets 1500 290
Prevalent Hepatocellular carcinoma
Base 990 750
Increased treatment 990 320
WHO targets 990 170
Liver-related deaths
Base 1000 900
Increased treatment 1000 530
WHO targets 1000 200
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number of viremic HCV infections would decrease by
80%; liver-related deaths, prevalent HCC and prevalent
decompensated cirrhosis would decrease by 80–85%
(Fig. 2 and Table 3).
Discussion
The availability of DAA therapy with its high SVR rates
has allowed Turkey to embark on reaching the WHO
targets for the elimination of viral hepatitis as a public
health threat by 2030. The cost of treatment in Turkey
is a major bottleneck to the large scale roll-out in the
country, despite DAA therapy being shown to be cost-
effective in other countries, when delivered at scale and
in combination with prevention and screening strategies
[28–30]. In Turkey, the average annual cost (excluding
hepatitis C drug costs) of a patient with chronic hepatitis
C, compensated cirrhosis, decompensated cirrhosis,
HCC and liver transplant is US$ 446.83, US$ 577.56,
US$ 1984.39, US$ 2474.15, US$ 42,469.27, respectively
[31]. To reach the WHO targets, early diagnosis and
treatment are crucial and cost-saving, as inaction or se-
vere disease costs significantly more. This study found
that in all three of the modelled treatment paradigms, by
2030, the total number of viremic infections, liver-
related deaths, HCC and decompensated cirrhosis would
decrease, which would be highest if the WHO targets
are achieved.
If a micro-elimination approach focuses on patients
already in the health system, screening, treatment and
prevention interventions can often be provided moreeasily, without additional burden on the health system.
Furthermore, as in other parts of the world, models of
care that tailor to the needs of sub-populations should
be considered whenever possible [32], if elimination is to
be achieved.
Addressing micro-elimination in subpopulations
Patients at high risk who are already in the health-care
system
Patients with advanced liver disease Such patients
have probably already been diagnosed and are being
followed up regularly [5]. As these patients are evaluated
at least once a year by a gastroenterologist, they could
easily be also evaluated for HCV.
Patients with advanced chronic kidney disease
Turkey has a well-organized and fully reimbursed
hemodialysis/peritoneal dialysis system for patients with
chronic kidney disease and almost all patients are
followed up by a dedicated dialysis centre. These centres
can therefore be included in a comprehensive evaluation
and yearly HCV screening programme of both current
and prospective patients.
Patients with certain inherited blood disorders (i.e.
hemophilia, thalassemia) Due to their requirement for
blood or blood component transfusion, these patients
are vulnerable to acquiring HCV. As they are closely
followed up by certain hospitals and/or special treatment
centres in Turkey, their HCV status can be evaluated by
including these institutions in plans for micro-
elimination.
Transplant recipients and patients on immune-
suppressive treatment During 2016, of 4,906 trans-
plants nationally, approximately 1,300–1,400 were liver
transplants. The number is increasing each year [33].
Such patients are subject to severe complications of in-
fection. The medical condition of these patients and
current reimbursement legislation require routine follow
up by the relevant medical specialty departments and
their records are kept properly. A plan that focuses on
the HCV status of patients in these transplantation cen-
tres can be easily implemented.
Persons who have already been diagnosed with HCV
but not treated yet Big dentistry clinics and many gen-
eral health-care settings routinely evaluate patients for
certain infections preoperatively, but often do not
adequately refer them. Surgeons, dentists and anaesthe-
siologists can be trained to detect such patients, and the
hospital information technology system improved to in-
stitute a warning for patients who test positive or
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relevant clinics.
Since the mid-1990s, all blood banks in Turkey rou-
tinely evaluate all blood donations for certain infections.
Anti-HCV-positive donors are informed about their situ-
ation, but there is no follow-up system. Hence, most of
them are not admitted to the relevant specialty clinics.
Blood bank personnel can be trained, and a referral and
follow-up system developed for such donors. Hospital
and blood bank records can also be evaluated retrospect-
ively to identify patients with a positive anti-HCV test
result. A dedicated team in each hospital or blood bank
can contact these patients and organize further testing
and referral procedures.
People at high risk due to demographic characteristics
People who were born before 1960 The use of non-
disposable medical equipment was common in Turkey
before 1990 and routine HCV screening for all blood
and blood products was not mandatory before the mid-
1990s. Therefore, those who underwent any kind of
medical procedure, got vaccination, or received any kind
of blood or blood product before the mid-1990s may
have been exposed to HCV. People born before 1970
were clearly at higher risk for acquiring HCV infection.
Local data from Turkey also confirmed this, which re-
vealed that the mean age of patients with positive anti-
HCV was 49 years in 2010 [4]. Therefore, a national plan
that includes evaluation of the HCV status of people
who were born before 1960 and/or have high alanine
aminotransferase/aspartate aminotransferase (ALT/AST)
levels would identify many patients who suffer from un-
diagnosed HCV and its complications.
People from certain geographic areas Living in south-
eastern Turkey is associated with a 2.1-fold increase in
the chances of being anti-HCV positive compared to liv-
ing in other areas of Turkey [4]. The Cappadocia region
also has a higher prevalence of HCV. A national HCV
screening strategy that targets HCV-prevalent areas,
such as Kirikhan district in Hatay city, can identify those
who are currently infected with HCV.
People with high-risk behaviours
People who inject drugs In Turkey, specialized addic-
tion centres (AMATEMs) provide inpatient and out-
patient health-care services to people who inject drugs.
Nationally, around 12,000 people were admitted to these
in 2015. The prevalence of anti-HCV positivity among
people who inject drugs was estimated to be around 40%
in 2015 [26].The benefits of providing training to health-care pro-
fessionals at AMATEMs and defining systems for refer-
ral and access to treatment for anti-HCV-positive
patients at these centres has been described previously
[34]. Freely accessible treatment of HCV in people who
inject drugs can prevent HCV transmission to unin-
fected people and reinfection among those treated.
Prisoners Prisoners are a vulnerable population and are
among the potential priority at-risk populations for
micro-elimination [35]. The continued use of drugs and
shared syringes, getting new tattoos, and other incidents
that cause contact with blood increase the risk of blood-
borne infections among prisoners [27]. A national plan
formulated jointly by both the Ministry of Health and
Ministry of Justice should include training of health-care
providers in prisons, screening of prisoners and defining
the methodology to access treatment.
Barriers to improving access to direct-acting antivirals in
Turkey
The current reimbursement conditions for DAAs are
flexible; however, treatment can be initiated only by gas-
troenterologists or infectious disease specialists in autho-
rized tertiary hospitals in 41 cities of Turkey. Based on
the outcomes of the meetings, it was recommended that
all gastroenterologists and infectious disease specialists,
regardless of hospital type and city, be authorized to
start DAA treatment by the national reimbursement
authority.
The majority of antiviral treatment-naive patients liv-
ing with HCV are at least at the F1 stage of fibrosis at
the time of diagnosis. Therefore, the requirement for
classifying antiviral treatment-naive patients by fibrosis
type with a documented biopsy has no practical benefit.
Moreover, the interventional nature of the biopsy may
cause some medical complications and patient discom-
fort [36]. This requirement for accessing treatment
should be removed, as in most countries of the world
[37].
In addition to the aforementioned barriers to improv-
ing HCV treatment access in Turkey, the lack of epi-
demiological data available in the country hinders
proper reporting and surveillance efforts. One solution
would be to simplify the cascade of care by using the
consensus definition to standardize HCV reporting and
monitor elimination effort progress across the country
and in all sub-populations [38].
Limitations
Our results had several methodological limitations. The
model was calibrated with the best available data, sup-
plemented by a Delphi process to gain agreement on all
inputs by national experts. The actual number of total
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addition, the model does not take into account the im-
pact (either on disease burden or economically) of re-
infection or comorbidities. More so, though this model
does not dynamically estimate new infections or reinfec-
tions, the high treatment rate required of the specified
elimination scenario, coupled with reduced treatment re-
strictions and prevention programs aimed at high-risk
groups, exceed the treated proportion specified in other
dynamic models. Lastly, the increases in treatment and
diagnostic levels may not be realistic, given the current
healthcare and economic constraints in Turkey. The
modelled scenarios use inputs for the number of diag-
nosed cases necessary to treat the indicated number of
patients at a sustained level. Finding undiagnosed cases
will become more difficult as the diagnosis rate increases.
Finally, a sensitivity analysis was not conducted in this
study. The uncertainty in HCV prevalence dominates all
previous sensitivity analyses and accounted for the major-
ity of the variance. However, the decisions and recom-
mendations here would still be the same. Thus, for the
purposes of supporting decisionmaking by the policy-
makers, only the deterministic results were presented.
Conclusions
Turkey has the potential to achieve the WHO HCV
elimination targets if it greatly increases the number of
individuals diagnosed and treated. The results of model-
ling the burden of HCV in Turkey and contextualizing
infected subpopulations in the overall infected popula-
tion showed the value of the micro-elimination approach
in reaching the WHO elimination targets. However, bet-
ter reported data and estimates are needed countrywide.
Further, all regions of the country should have access to
DAAs, and the recent removal of the requirement for a
liver biopsy to initiate treatment should facilitate the
process. These investments will pay off by saving lives and
averting costly interventions that will occur in the future if
the WHO 2030 targets are not met.
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